Abstract
Severe Maroteaux–Lamy syndrome is usually fatal in teenage or early adult life. Until recently, allogeneic bone marrow transplantation was the only form of enzyme replacement. We report the first successful transplant using CD34 selected, mobilised allogeneic blood cells for an inborn error of metabolism. A busulphan, cyclophosphamide, melphalan and antithymocyte globulin conditioning regimen was used as myeloablative therapy. Allogeneic CD34 selected granulocyte colony-stimulating factor (G-CSF)-mobilised blood cells from a HLA-identical sibling were used for the transplant. Haemopoietic reconstitution occurred on day 10 post-transplant with normal N-acetylgalactosamine-4-sulphatase levels. Infectious and graft-versus-host disease (GVHD) complications were minimal. We suggest that CD34 selected, mobilised allogeneic blood cells are a safe form of enzyme replacement therapy in Maroteaux–Lamy syndrome and should be considered in other metabolic diseases where the benefits of haemopoietic transplantation are proven.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alvaro, F., Toogood, I., Fletcher, J. et al. Allogeneic CD34 selected peripheral stem cell transplant for Maroteaux–Lamy syndrome (mucopolysaccharidosis type VI): rapid haemopoietic and biochemical reconstitution. Bone Marrow Transplant 21, 419–421 (1998). https://doi.org/10.1038/sj.bmt.1701092
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701092
Keywords
This article is cited by
-
Umbilical cord blood transplantation for Maroteaux–Lamy syndrome (mucopolysaccharidosis type VI)
Bone Marrow Transplantation (2000)